Vitamin D3 ( DrugBank: Vitamin D3 )


12 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病4
13多発性硬化症/視神経脊髄炎25
20副腎白質ジストロフィー1
46悪性関節リウマチ2
49全身性エリテマトーデス4
51全身性強皮症1
53シェーグレン症候群1
60再生不良性貧血1
65原発性免疫不全症候群2
96クローン病13
97潰瘍性大腸炎4
299嚢胞性線維症8

6. パーキンソン病


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01119131
(ClinicalTrials.gov)
May 201123/4/2010Effects of Vitamin D in Parkinson's Disease (PD)The Effects of Vitamin D on Balance in Persons With PDParkinson Disease;Accidental FallsDrug: Vitamin D3;Dietary Supplement: calcium;Other: PlaceboVA Office of Research and DevelopmentOregon Health and Science UniversityCompleted50 Years99 YearsAll101Phase 2United States
2NCT00907972
(ClinicalTrials.gov)
September 200922/5/2009The Effects of Vitamin D and Bone Loss in Parkinson's DiseaseEffect of Vitamin D3 Supplementation in Parkinson's Disease Patients - A Pilot StudyParkinson DiseaseDietary Supplement: Vitamin D3;Other: PlaceboMemorial Medical CenterDepartment of DefenseCompleted18 YearsN/ABoth23Phase 2United States
3JPRN-UMIN000001841
2009/04/0102/04/2009A randomized, double blind, comparative study of vitamin D3 versus placebo in patients with Parkinson disease aged between 45 and 85 years old to improve neurological signs and quality of lifeA randomized, double blind, comparative study of vitamin D3 versus placebo in patients with Parkinson disease aged between 45 and 85 years old to improve neurological signs and quality of life - RCT with vitamin D for Parkinson disease Parkinson diseaseVitamin D3
placebo
Jikei University School of MedicineNULLComplete: follow-up complete45years-old85years-oldMale and Female120Not selectedJapan
4NCT00571285
(ClinicalTrials.gov)
June 20077/12/2007Clinical Effects of Vitamin D Repletion in Patients With Parkinson's DiseaseClinical Effects of Vitamin D Repletion in Patients With Parkinson's DiseaseParkinson's DiseaseDietary Supplement: Vitamin D3;Dietary Supplement: Vitamin D3 - high dose;Dietary Supplement: PlaceboEmory UniversityNULLTerminated18 Years89 YearsAll31Phase 4United States

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05340985
(ClinicalTrials.gov)
July 20222/3/2022Investigating the Effects of Hydroxyvitamin D3 on Multiple SclerosisInvestigating the Effects of Hydroxyvitamin D3 Versus Vitamin D3 on Clinical, and Radiologic Progress and Th17/Tregs Balance in MS Patients: A Randomized, Clinical Trial- a Pilot StudyMultiple Sclerosis, Relapsing-Remitting;Adult ALL;Vitamin D3 DeficiencyDietary Supplement: 25(OH)D3;Dietary Supplement: vitamin D3Tehran University of Medical SciencesBoston UniversityNot yet recruiting18 Years55 YearsAll54Phase 4NULL
2NCT03610139
(ClinicalTrials.gov)
May 21, 201813/7/2018Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis PatientsLongitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients: A Single-Blind Randomized Clinical TrialMultiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting;Clinically Isolated Syndrome;Clinically Isolated Syndrome, CNS Demyelinating;Vitamin D3 DeficiencyDietary Supplement: Vitamin D3American University of Beirut Medical CenterNULLRecruiting18 YearsN/AAll162N/ALebanon
3NCT02696590
(ClinicalTrials.gov)
July 201518/2/2016High Dose Oral Versus Intramuscular Vitamin D3 Supplementation In Multiple Sclerosis PatientsIsfahan University of Medical SciencesRelapsing Remitting Multiple SclerosisDietary Supplement: Vitamin D3Isfahan University of Medical SciencesNULLCompleted23 Years59 YearsBoth200N/AIran, Islamic Republic of
4NCT02096133
(ClinicalTrials.gov)
October 13, 201421/3/2014Vitamin D3 and the Stress-axis in MSRegulation of the Stress-axis by Vitamin D3 in Subjects With Multiple Sclerosis; a Double-blinded, Randomized, Placebo-controlled StudyMultiple SclerosisDrug: Cholecalciferol;Other: Placebo comparatorAcademic MS Center LimburgNULLTerminated18 YearsN/AFemale54Phase 2Netherlands
5NCT01817166
(ClinicalTrials.gov)
July 16, 201320/3/2013Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated SyndromeMulticentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years.Multiple SclerosisDrug: Vitamin D;Drug: Placebo;Other: Imaging;Biological: Lumbar puncture;Biological: Blood sampling;Biological: Urine samplesCentre Hospitalier Universitaire de NimesNULLActive, not recruiting18 Years56 YearsAll316Phase 3France
6NCT01753375
(ClinicalTrials.gov)
January 201317/12/2012Role of Vitamin D in Reducing the Relapse Rate in Patients With Multiple SclerosisRole of Vitamin D on the Relapse Rate of Multiple SclerosisMultiple SclerosisDietary Supplement: Vitamin D3;Dietary Supplement: PlaceboAlJohara M AlQuaiz, M.D.NULLNot yet recruiting18 Years55 YearsBoth200Phase 2Saudi Arabia
7NCT01728922
(ClinicalTrials.gov)
November 6, 20128/11/2012Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated SyndromeDose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome and Healthy Control Participants. An Exploratory Double Blind Placebo Randomised Controlled Study.Clinically Isolated Syndrome;Multiple SclerosisDietary Supplement: 5000IU vitamin D;Dietary Supplement: 10000IU vitamin D;Other: PlaceboUniversity College DublinUniversity of Dublin, Trinity College;St Vincent's University Hospital, IrelandCompleted18 Years55 YearsAll64Phase 1/Phase 2Ireland
8NCT01490502
(ClinicalTrials.gov)
March 20126/12/2011Vitamin D Supplementation in Multiple SclerosisA Randomized Controlled Trial of Vitamin D Supplementation in Multiple SclerosisRelapsing Remitting Multiple SclerosisDrug: Vitamin D3Johns Hopkins UniversityOregon Health and Science University;University of California, San Francisco;Washington University School of Medicine;Icahn School of Medicine at Mount Sinai;University of Pennsylvania;Yale University;The Cleveland Clinic;University of Rochester;Stanford University;University of Virginia;Swedish Medical Center;Anne Arundel Health System Research Institute;Columbia University;University of Massachusetts, Worcester;Dignity HealthCompleted18 Years50 YearsAll172Phase 3United States
9EUCTR2010-020328-23-PT
(EUCTR)
06/01/201217/11/2011Supplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment.A three-arm, randomized, double-blind, placebo controlled, multicenter,phase II study to evaluate the efficacy of Vigantol® oil as add-ontherapy in subjects with Relapsing-Remitting Multiple Sclerosis receivingtreatment with 44 µg tiw of Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment. - SOLAR Relapsing-Remitting Multiple Sclerosis
MedDRA version: 14.0;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Vigantol Oel
Product Name: Vigantol Oil
Product Code: 200106 or EMD 28162
INN or Proposed INN: COLECALCIFEROL
Other descriptive name: Cholecalciferol, Vitamin D3
Merck Serono SA - Geneva, an affiliate of Merck KGaA,NULLNot RecruitingFemale: yes
Male: yes
358Phase 2Portugal;Estonia;Finland;Lithuania;Austria;Switzerland;Italy;Hungary;Belgium;Denmark;Norway;Germany;Latvia;Netherlands
10EUCTR2010-020328-23-AT
(EUCTR)
23/11/201128/10/2011Supplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment.A three-arm, randomized, double-blind, placebo controlled, multicenter,phase II study to evaluate the efficacy of Vigantol® oil as add-ontherapy in subjects with Relapsing-Remitting Multiple Sclerosis receivingtreatment with 44 µg tiw of Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment. - SOLAR Relapsing-Remitting Multiple Sclerosis
MedDRA version: 14.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Vigantol Oel
Product Name: Vigantol Oil
Product Code: 200106 or EMD 28162
INN or Proposed INN: COLECALCIFEROL
Other descriptive name: Cholecalciferol, Vitamin D3
Merck Serono SA - Geneva, an affiliate of Merck KGaA,NULLNot RecruitingFemale: yes
Male: yes
358Phase 2Portugal;Estonia;Finland;Lithuania;Austria;Switzerland;Italy;Hungary;Belgium;Denmark;Norway;Germany;Latvia;Netherlands
11EUCTR2010-020328-23-LV
(EUCTR)
19/07/201116/05/2011Supplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment.A three-arm, randomized, double-blind, placebo controlled, multicenter,phase II study to evaluate the efficacy of Vigantol® oil as add-ontherapy in subjects with Relapsing-Remitting Multiple Sclerosis receivingtreatment with 44 µg tiw of Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment. - SOLAR Relapsing-Remitting Multiple Sclerosis
MedDRA version: 16.0;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Vigantol Oel
Product Name: Vigantol Oil
Product Code: 200106 or EMD 28162
INN or Proposed INN: COLECALCIFEROL
Other descriptive name: Cholecalciferol, Vitamin D3
Merck SeronoNULLNot RecruitingFemale: yes
Male: yes
230Phase 2Portugal;Estonia;Finland;Lithuania;Austria;Switzerland;Italy;Belgium;Denmark;Latvia;Norway;Germany;Netherlands
12EUCTR2010-020328-23-LT
(EUCTR)
09/05/201102/03/2011Supplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment.A three-arm, randomized, double-blind, placebo controlled, multicenter,phase II study to evaluate the efficacy of Vigantol® oil as add-ontherapy in subjects with Relapsing-Remitting Multiple Sclerosis receivingtreatment with 44 µg tiw of Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment. - SOLAR Relapsing-Remitting Multiple Sclerosis
MedDRA version: 14.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Vigantol Oil
Product Name: Vigantol Oil
Product Code: 200106 or EMD 28162
INN or Proposed INN: CHOLECALCIFEROL
Other descriptive name: Cholecalciferol, Vitamin D3
Merck SeronoNULLNot RecruitingFemale: yes
Male: yes
230Phase 2Portugal;Estonia;Finland;Lithuania;Austria;Switzerland;Italy;Belgium;Denmark;Norway;Germany;Latvia;Netherlands
13EUCTR2010-020328-23-EE
(EUCTR)
26/04/201121/03/2011Supplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment.A three-arm, randomized, double-blind, placebo controlled, multicenter, phase II study to evaluate the efficacy of Vigantol® oil as add-on therapy in subjects with Relapsing-Remitting Multiple Sclerosis receiving treatment with 44 µg tiw of Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment. - SOLAR Relapsing-Remitting Multiple Sclerosis
MedDRA version: 14.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Vigantol Oel
Product Name: Vigantol Oil
Product Code: EMD 28162
INN or Proposed INN: COLECALCIFEROL
Other descriptive name: Cholecalciferol, Vitamin D3
Merck SeronoNULLNot RecruitingFemale: yes
Male: yes
230Phase 2Portugal;Estonia;Finland;Lithuania;Austria;Switzerland;Italy;Belgium;Denmark;Norway;Germany;Latvia;Netherlands
14EUCTR2010-020328-23-BE
(EUCTR)
01/04/201118/11/2010A three-arm, randomized, double-blind, placebo controlled, multicenter, phase II study to evaluate the efficacy of Vigantol® oil as add-on therapy in subjects with Relapsing-Remitting Multiple Sclerosis receiving treatment with Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment. - SOLARA three-arm, randomized, double-blind, placebo controlled, multicenter, phase II study to evaluate the efficacy of Vigantol® oil as add-on therapy in subjects with Relapsing-Remitting Multiple Sclerosis receiving treatment with Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment. - SOLAR Relapsing-Remitting Multiple Sclerosis
MedDRA version: 12.1;Level: LLT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis
Trade Name: Vigantol Oel
Product Name: Vigantol Oil
Product Code: EMD 28162
INN or Proposed INN: CHOLECALCIFEROL
Other descriptive name: Cholecalciferol, Vitamin D3
Merck Serono SA-Geneva an affiliate of Merck KgaA, DarmstadtNULLNot RecruitingFemale: yes
Male: yes
358Phase 2Portugal;Estonia;Finland;Belgium;Lithuania;Austria;Denmark;Latvia;Germany;Netherlands;Italy
15EUCTR2010-020328-23-DE
(EUCTR)
31/01/201127/10/2010Supplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment.A three-arm, randomized, double-blind, placebo controlled, multicenter, phase II study to evaluate the efficacy of Vigantol® oil as add-on therapy in subjects with Relapsing-Remitting Multiple Sclerosis receiving treatment with 44 µg tiw of Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment. - SOLAR Relapsing-Remitting Multiple Sclerosis
MedDRA version: 18.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Vigantol Oel
Product Name: Vigantol Oil
Product Code: EMD 28162
INN or Proposed INN: CHOLECALCIFEROL
Other descriptive name: Cholecalciferol, Vitamin D3
Merck SeronoNULLNot RecruitingFemale: yes
Male: yes
230Phase 2Portugal;Estonia;Finland;Lithuania;Austria;Italy;Switzerland;Belgium;Denmark;Germany;Latvia;Netherlands;Norway
16EUCTR2010-020328-23-NL
(EUCTR)
06/01/201116/09/2010A three-arm, randomized, double-blind, placebo controlled, multicenter, phase II study to evaluate the efficacy of Vigantol® oil as add-on therapy in subjects with Relapsing-Remitting Multiple Sclerosis receiving treatment with Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment. - SOLARA three-arm, randomized, double-blind, placebo controlled, multicenter, phase II study to evaluate the efficacy of Vigantol® oil as add-on therapy in subjects with Relapsing-Remitting Multiple Sclerosis receiving treatment with Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment. - SOLAR Relapsing-Remitting Multiple Sclerosis
MedDRA version: 12.1;Level: LLT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis
Trade Name: Vigantol Oel
Product Name: Vigantol Oil
Product Code: EMD 28162
INN or Proposed INN: COLECALCIFEROL
Other descriptive name: Cholecalciferol, Vitamin D3
Merck Serono The Netherlands - a division of Merck B.V.NULLNot RecruitingFemale: yes
Male: yes
358Phase 2Portugal;Estonia;Finland;Belgium;Lithuania;Austria;Denmark;Latvia;Germany;Netherlands;Italy
17EUCTR2010-020328-23-DK
(EUCTR)
09/12/201008/11/2010Supplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment.A three-arm, randomized, double-blind, placebo controlled, multicenter,phase II study to evaluate the efficacy of Vigantol® oil as add-ontherapy in subjects with Relapsing-Remitting Multiple Sclerosis receivingtreatment with 44 µg tiw of Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment. - SOLAR Relapsing-Remitting Multiple Sclerosis
MedDRA version: 14.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Vigantol Oel
Product Name: Vigantol Oil
Product Code: 200106 or EMD 28162
INN or Proposed INN: COLECALCIFEROL
Other descriptive name: Cholecalciferol, Vitamin D3
Merck SeronoNULLNot RecruitingFemale: yes
Male: yes
230Phase 2Portugal;Estonia;Finland;Lithuania;Austria;Switzerland;Italy;Belgium;Denmark;Norway;Germany;Latvia;Netherlands
18NCT01667796
(ClinicalTrials.gov)
November 201013/8/2012Pharmacokinetics of Vitamin D in Multiple Sclerosis and in HealthPharmacodynamic and Immunologic Effects of Vitamin D Supplementation in Patients With Multiple Sclerosis and Healthy ControlsMultiple Sclerosis, Relapsing-remittingDietary Supplement: Vitamin D3Johns Hopkins UniversityUniversity of California, San Francisco;National Multiple Sclerosis SocietyCompleted18 Years60 YearsFemale57N/AUnited States
19EUCTR2010-020328-23-FI
(EUCTR)
21/10/201027/08/2010Supplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment.A three-arm, randomized, double-blind, placebo controlled, multicenter,phase II study to evaluate the efficacy of Vigantol® oil as add-ontherapy in subjects with Relapsing-Remitting Multiple Sclerosis receivingtreatment with 44 µg tiw of Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment. - SOLAR Relapsing-Remitting Multiple Sclerosis
MedDRA version: 14.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Vigantol Oel
Product Name: Vigantol Oil
Product Code: 200106 or EMD 28162
INN or Proposed INN: COLECALCIFEROL
Other descriptive name: Cholecalciferol, Vitamin D3
Merck SeronoNULLNot RecruitingFemale: yes
Male: yes
230Phase 2Portugal;Estonia;Finland;Lithuania;Austria;Switzerland;Italy;Belgium;Denmark;Norway;Germany;Latvia;Netherlands
20NCT01005095
(ClinicalTrials.gov)
October 201029/10/2009The Effects of Interferon Beta Combined With Vitamin D on Relapsing Remitting Multiple Sclerosis PatientsA One Year Prospective, Randomized, Double Blind Interventional Study to Assess Tolerability, Quality of Life and Immunomodulation With Interferon Beta Combined With Vitamin D in Patients With Relapsing Remitting Multiple SclerosisMULTIPLE SCLEROSISDietary Supplement: Vitamin D3Carmel Medical CenterNULLTerminated18 Years65 YearsBoth45Phase 4Israel
21NCT01024777
(ClinicalTrials.gov)
March 20102/12/2009Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple SclerosisA Pilot Study to Assess the Relative Safety and Immunology Effects of Low Dose Versus High Dose Cholecalciferol Supplementation in Patients With Multiple SclerosisMultiple Sclerosis;Vitamin D DeficiencyDrug: CholecalciferolJohns Hopkins UniversityNULLCompleted18 Years55 YearsBoth40Phase 1United States
22NCT01198132
(ClinicalTrials.gov)
November 20098/9/2010A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times WeeklyA Multicentre, Randomised, Double-blind, Placebo-controlled Study of the Efficacy of Supplementary Treatment With Cholecalciferol (Vitamin D3) in Patients With Relapsing- Multiple Sclerosis (RMS) Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times WeeklyMultiple SclerosisDietary Supplement: Cholecalciferol (Vitamin D3);Dietary Supplement: Placebo;Drug: RebifMerck KGaAMerck Serono S.A.S, FranceCompleted18 Years65 YearsAll129Phase 2France
23NCT00940719
(ClinicalTrials.gov)
August 200915/7/2009Vitamin D3 Supplementation and the T Cell Compartment in Multiple Sclerosis (MS)The Effects of Vitamin D3 Supplementation on the T Cell Compartment in Multiple Sclerosis; a Pilot StudyMultiple SclerosisDietary Supplement: vitamin D3Maastricht University Medical CenterOrbis Medical CentreCompleted18 YearsN/ABoth15N/ANetherlands
24NCT00644904
(ClinicalTrials.gov)
July 200624/3/2008Safety Trial of High Dose Oral Vitamin D3 With Calcium in Multiple SclerosisA Phase I/II Dose-Escalation Trial of Vitamin D3 With Calcium Supplementation in Patients With Multiple SclerosisMultiple SclerosisDietary Supplement: Vitamin D3University of TorontoDirect MS-Proactive Charity;Multiple Sclerosis Society of CanadaCompleted18 Years55 YearsBoth49Phase 1/Phase 2Canada
25EUCTR2014-000728-97-NL
(EUCTR)
08/05/2014Regulation of the stress-axis by vitamin D in subjects with multiple sclerosis.Regulation of the stress-axis by vitamin D3 in subjects with multiple sclerosis; a double-blinded, randomized, placebo-controlled study - Vitamin D3 and the stress-axis in MS Relapsing remitting multiple sclerosis
MedDRA version: 18.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Vigantol® Oil
Product Name: Vigantol® Oil
Product Code: EMD 28162
Academic MS Center LimburgNULLNot RecruitingFemale: yes
Male: no
Phase 2Netherlands

20. 副腎白質ジストロフィー


臨床試験数 : 61 薬物数 : 90 - (DrugBank : 31) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 126
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02595489
(ClinicalTrials.gov)
November 21, 201629/10/2015A Pilot Study of Vitamin D in Boys With X-linked AdrenoleukodystrophyA Pilot Study of Vitamin D in Boys With X-linked AdrenoleukodystrophyX-linked AdrenoleukodystrophyDietary Supplement: vitamin D3Stanford UniversityNational Institute of Neurological Disorders and Stroke (NINDS);Hugo W. Moser Research Institute at Kennedy Krieger, Inc.;ALD Connect, Inc.Completed18 Months25 YearsMale21Phase 1United States

46. 悪性関節リウマチ


臨床試験数 : 4,356 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05078502
(ClinicalTrials.gov)
June 1, 20214/10/2021Role of Vitamin D3 Supplementation With Conventional Synthetic Disease Modifying Antirheumatic Drugs(csDMARD) in Rheumatoid Arthritis PatientsRole of Vitamin D3 Supplementation With Conventional Synthetic Disease Modifying Antirheumatic Drugs (csDMARD) in Rheumatoid Arthritis Patients: Randomized Double-blind Placebo Controlled TrialRheumatoid ArthritisDietary Supplement: Vitamin D3Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshNULLCompleted18 Years70 YearsAll58N/ABangladesh
2NCT02633332
(ClinicalTrials.gov)
February 201530/11/2015Use of Well Known Drugs for New Destination - RA Improvement (RANT)Observational Retrospective Study About the Use of Well Known Drugs in Combination to Obtain a New Drug to Improve Quality of Life/Health in Patient With Diagnosed Rheumatoid Arthritis Not Responding to Commonly Used TreatmentsRheumatoid Arthritis;Autoimmune Diseases;Disorder of Synovium;Sjogren's Syndrome;Acute and Chronic Inflammation;Disorder of Pleura and Pleural Cavity;Felty's Syndrome;Rheumatoid NodulesDrug: Vitamin D3;Drug: Lipitor®;Drug: Acycloguanosine;Drug: Tetracycline;Drug: methotrexate;Drug: etanerceptUniversità Popolare Homo & NaturaNULLCompleted18 Years75 YearsBoth15Phase 1Italy

49. 全身性エリテマトーデス


臨床試験数 : 993 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05326841
(ClinicalTrials.gov)
October 3, 202123/3/2022Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients .Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus PatientsLupus Erythematosus, Systemic;Cholecalciferol Supplementation;Disease Activity;Quality of LifeDrug: Vitamin D3Dr Cipto Mangunkusumo General HospitalNULLCompleted18 Years60 YearsFemale60Phase 3Indonesia
2NCT03155477
(ClinicalTrials.gov)
June 10, 201613/5/2017Effect Of Curcuma Xanthorrhiza and Vitamin D3 Supplementation in SLE Patients With Hypovitamin DEffect Of Curcuma Xanthorrhiza Supplementation In Systemic Lupus Erythematosus Patients (SLE) With Hypovitamin D Which Were Given Vitamin D3 Towards Disease Activity (SLEDAI), Interleukin-6 (IL-6) And Tumor Growth Factor-ß1 (TGF-ß1) SerumSLEDietary Supplement: Cholecalciferol and C. Xanthorrhiza;Dietary Supplement: Cholecalciferol and placeboSaiful Anwar HospitalNULLCompleted18 Years45 YearsFemale39N/ANULL
3NCT01709474
(ClinicalTrials.gov)
June 201316/10/2012Vitamin D3 Treatment in Pediatric Systemic Lupus ErythematosusVitamin D3 Effects on Immune Function in Pediatric Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythematosusDrug: Vitamin D3 6000 IU;Drug: Vitamin D3 400 IUNational Institute of Allergy and Infectious Diseases (NIAID)Autoimmunity Centers of ExcellenceTerminated5 Years20 YearsAll7Phase 2United States
4NCT00710021
(ClinicalTrials.gov)
November 20081/7/2008Vitamin D3 in Systemic Lupus ErythematosusEffect of Vitamin D3 on the IFN Alpha Signature in Patients With Systemic Lupus Erythematosus (ALE02)Systemic Lupus Erythematosus;SLE;LupusDrug: Vitamin D3;Drug: Vitamin D3 placeboNational Institute of Allergy and Infectious Diseases (NIAID)Autoimmunity Centers of ExcellenceCompleted18 YearsN/AAll57Phase 2United States

51. 全身性強皮症


臨床試験数 : 525 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04822038
(ClinicalTrials.gov)
June 1, 201712/2/2021Immunomodulating Effects of Supplementation With 25-OH Vitamin DImmunomodulating Effects of Supplementation With 25 oh Vitamin D in Adults With Scleroderma and Hypovitaminosis DVitamin D Deficiency;Scleroderma, SystemicDietary Supplement: Vitamin D3;Other: Dietary recommendationsCoordinación de Investigación en Salud, MexicoNULLCompleted18 YearsN/AAll49N/AMexico

53. シェーグレン症候群


臨床試験数 : 305 薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02633332
(ClinicalTrials.gov)
February 201530/11/2015Use of Well Known Drugs for New Destination - RA Improvement (RANT)Observational Retrospective Study About the Use of Well Known Drugs in Combination to Obtain a New Drug to Improve Quality of Life/Health in Patient With Diagnosed Rheumatoid Arthritis Not Responding to Commonly Used TreatmentsRheumatoid Arthritis;Autoimmune Diseases;Disorder of Synovium;Sjogren's Syndrome;Acute and Chronic Inflammation;Disorder of Pleura and Pleural Cavity;Felty's Syndrome;Rheumatoid NodulesDrug: Vitamin D3;Drug: Lipitor®;Drug: Acycloguanosine;Drug: Tetracycline;Drug: methotrexate;Drug: etanerceptUniversità Popolare Homo & NaturaNULLCompleted18 Years75 YearsBoth15Phase 1Italy

60. 再生不良性貧血


臨床試験数 : 245 薬物数 : 318 - (DrugBank : 86) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 166
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03176849
(ClinicalTrials.gov)
November 1, 201726/5/2017A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCTA Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT to Prevent Vitamin D Deficiency and Insufficiency During TransplantVitamin D Deficiency;Stem Cell Transplant Complications;Pediatric Cancer;Blood Disorder;Pediatric Acute Myeloid Leukemia;Pediatric Acute Lymphoid Leukemia;Myelodysplastic Syndromes;Sickle Cell Anemia in Children;Aplastic Anemia;Thalassemia in ChildrenDietary Supplement: Vitamin D3;Dietary Supplement: Standard Vitamin D3 SupplementationPhoenix Children's HospitalNULLCompleted1 Year25 YearsAll49Phase 4United States

65. 原発性免疫不全症候群


臨床試験数 : 500 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03984890
(ClinicalTrials.gov)
August 1, 20195/12/2018Vitamin D3 For CGD Patients With BCGosis/ItisEffect of Vitamin D3 Supplementation on Chronic Granulomatous Disease Patients With BCGosis/ItisVitamin D3;Chronic-granulomatous Disease;BCGDrug: Vitamin D3;Drug: Traditional treatment of CGD and TBChildren's Hospital of Fudan UniversityNULLRecruitingN/A18 YearsAll50Phase 2/Phase 3China
2NCT01131858
(ClinicalTrials.gov)
March 201026/5/2010Study of Vitamin D3 Substitution to Patients With Primary ImmunodeficiencyA Placebo Controlled Double Blinded Study of Vitamin D3 Substitution to Patients With Primary ImmunodeficiencyPrimary Immune Deficiency DisorderDrug: Vigantol;Drug: PlaceboKarolinska University HospitalNULLCompleted18 Years75 YearsBoth140Phase 1/Phase 2Sweden

96. クローン病


臨床試験数 : 2,442 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04991324
(ClinicalTrials.gov)
September 21, 202227/7/2021Cholecalciferol Comedication in IBD - the 5C-studyCholecalciferol Comedication in Patients With Chronic Inflammatory Bowel Diseases (Crohn's Disease or Ulcerative Colitis) - the 5C-studyInflammatory Bowel DiseasesDrug: Vitamin D3University Hospital, Basel, SwitzerlandNULLRecruiting18 YearsN/AAll150Phase 3Switzerland
2NCT04225819
(ClinicalTrials.gov)
October 1, 20203/1/2020Adjunctive Treatment With Vitamin D3 in Patients With Active IBDAdjunctive Treatment With Vitamin D3 in Patients With Active IBD (ACTIVATED): A Randomized, Double-blind, Placebo-controlled TrialIBD;Inflammatory Bowel Diseases;Crohn Disease;Ulcerative Colitis;Vitamin D3 DeficiencyDietary Supplement: Vitamin D3;Other: PlaceboMassachusetts General HospitalNULLRecruiting18 YearsN/AAll100N/AUnited States
3NCT03999580
(ClinicalTrials.gov)
February 7, 202024/6/2019The Vitamin D in Pediatric Crohn's Disease ( ViDiPeC-2 )A Pragmatic Randomized Controlled Trial on High Dose Vitamin D to Prevent Relapses of Crohn's Disease in ChildrenCrohn DiseaseDrug: vitamin D3Jantchou PrevostNULLRecruiting4 Years18 YearsAll316Phase 3Canada
4NCT02186275
(ClinicalTrials.gov)
February 20164/7/2014The Vitamin D in Pediatric Crohn's DiseaseRandomized Controlled Trial of High Dose Vitamin D in Children With Newly Diagnosed Crohn's Disease for the Prevention of RelapsesCrohn's DiseaseDrug: Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day;Drug: Vitamin D3 800 UI/day then 800 UI/daySt. Justine's HospitalCanadian Institutes of Health Research (CIHR)Completed9 Years18 YearsAll25Phase 3Canada
5EUCTR2013-002838-20-BE
(EUCTR)
09/12/201415/09/2014The effect of Vitamin D to prevent post-operative relapse of Crohn's DiseaseThe effect of Vitamin D3 to prevent post-operative relapse of Crohn’s Disease: a placebo-controlled randomized trial (DETECT) - DETECT Crohn's Disease
MedDRA version: 19.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Trade Name: D-CURA
Product Name: D-Cura
INN or Proposed INN: Cholecalciferol
Other descriptive name: CHOLECALCIFEROL CONCENTRATE (WATER-DISPERSIBLE FORM)
Academic Medical CenterNULLNot RecruitingFemale: yes
Male: yes
142Phase 3Belgium;Netherlands
6NCT04606017
(ClinicalTrials.gov)
January 1, 201425/10/2020Effect of Vitamin D Supplementation on Infliximab Response in Patients With Crohn's DiseaseInfluence of Vitamin D3 Supplementation on Infliximab Efficacy in Chinese Patients With Crohn's Disease: A Retrospective Cohort StudyCrohn Disease;Vitamin D Deficiency;Vitamin D SupplementDrug: Caltrate PillSecond Affiliated Hospital of Wenzhou Medical UniversityNULLCompleted18 YearsN/AAll70China
7NCT02615288
(ClinicalTrials.gov)
January 201423/11/2015High Dose Vitamin D3 in Crohn's DiseaseImpact of High Dose Vitamin D3 Supplementation in Treatment of Crohn's Disease in Remission: A Randomized Double-blind Controlled StudyCrohn's DiseaseDietary Supplement: Vitamin D3McMaster UniversityCanadian Association of GastroenterologyCompleted18 Years70 YearsBoth40N/ANULL
8EUCTR2013-002838-20-NL
(EUCTR)
12/11/201306/09/2013The effect of Vitamin D to prevent post-operative relapse of Crohn's DiseaseThe effect of Vitamin D3 to prevent post-operative relapse of Crohn’s Disease: a placebo-controlled randomized trial (DETECT) - DETECT Crohn's Disease
MedDRA version: 18.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Trade Name: InVita D3
INN or Proposed INN: Colecalciferol
Other descriptive name: CHOLECALCIFEROL CONCENTRATE
Academic Medical CenterNULLNot RecruitingFemale: yes
Male: yes
142Phase 3Belgium;Netherlands
9NCT01864616
(ClinicalTrials.gov)
July 201322/5/2013The Impact of Vitamin D on Disease Activity in Crohn's DiseaseCrohn DiseaseDietary Supplement: Vitamin D3University of SaskatchewanDania Alrefai;Dr.Jennifer Jones;Dr.Hani Jawa;Dr.Wael El-matary;Saudi Arabian Cultural BureauTerminated16 Years70 YearsAll9N/ACanada;Saudi Arabia
10NCT02010762
(ClinicalTrials.gov)
February 201310/12/2013The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's DiseaseThe Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease: a Placebo-controlled Randomized TrialCrohn's DiseaseDrug: Vitamin D;Drug: PlaceboAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)NULLCompleted18 YearsN/AAll142Phase 4Netherlands
11NCT01692808
(ClinicalTrials.gov)
October 201217/9/2012Bioavailability of Vitamin D in Children and Adolescents With Crohn's DiseaseBioavailability of Vitamin D in Children and Adolescents With Crohn's Disease.Crohn's DiseaseDrug: Vitamin D3 3000 UI daily;Drug: Vitamin D3 4000 UI dailySt. Justine's HospitalNULLCompleted10 Years18 YearsBoth20Phase 2Canada
12NCT01877577
(ClinicalTrials.gov)
April 201211/6/2013Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis DSupplementation of Vitamin D3 (Cholecalciferol) in Patients With Inflammatory Bowel Diseases (IBD) and Hypovitaminosis D: A Prospective Randomized Controlled Trial.Crohn's Disease (CD);Ulcerative Colitis (UC)Dietary Supplement: Vitamin D3University of California, San FranciscoNULLCompleted18 YearsN/ABoth30N/AUnited States
13NCT01369667
(ClinicalTrials.gov)
April 20127/6/2011Vitamin D Supplementation in Adult Crohn's DiseaseVitamin D and Immunomodulation: Effects in Crohn's DiseaseCrohn's DiseaseDietary Supplement: Vitamin D3;Other: PlaceboUniversity of Dublin, Trinity CollegeQueen Mary University of LondonCompleted18 Years75 YearsBoth117Phase 4Ireland

97. 潰瘍性大腸炎


臨床試験数 : 2,630 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04991324
(ClinicalTrials.gov)
September 21, 202227/7/2021Cholecalciferol Comedication in IBD - the 5C-studyCholecalciferol Comedication in Patients With Chronic Inflammatory Bowel Diseases (Crohn's Disease or Ulcerative Colitis) - the 5C-studyInflammatory Bowel DiseasesDrug: Vitamin D3University Hospital, Basel, SwitzerlandNULLRecruiting18 YearsN/AAll150Phase 3Switzerland
2NCT04225819
(ClinicalTrials.gov)
October 1, 20203/1/2020Adjunctive Treatment With Vitamin D3 in Patients With Active IBDAdjunctive Treatment With Vitamin D3 in Patients With Active IBD (ACTIVATED): A Randomized, Double-blind, Placebo-controlled TrialIBD;Inflammatory Bowel Diseases;Crohn Disease;Ulcerative Colitis;Vitamin D3 DeficiencyDietary Supplement: Vitamin D3;Other: PlaceboMassachusetts General HospitalNULLRecruiting18 YearsN/AAll100N/AUnited States
3NCT01640496
(ClinicalTrials.gov)
July 201211/7/2012Vitamin D Treatment in Ulcerative ColitisVitamin D Treatment in Ulcerative ColitisUlcerative Colitis;Inflammatory Bowel DiseaseDrug: Vitamin D3;Other: PlaceboUniversity of ChicagoNorth Shore University HospitalWithdrawn18 YearsN/ABoth0N/AUnited States
4NCT01877577
(ClinicalTrials.gov)
April 201211/6/2013Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis DSupplementation of Vitamin D3 (Cholecalciferol) in Patients With Inflammatory Bowel Diseases (IBD) and Hypovitaminosis D: A Prospective Randomized Controlled Trial.Crohn's Disease (CD);Ulcerative Colitis (UC)Dietary Supplement: Vitamin D3University of California, San FranciscoNULLCompleted18 YearsN/ABoth30N/AUnited States

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04118010
(ClinicalTrials.gov)
March 13, 20204/10/2019Vitamin D and Prebiotics for Intestinal Health in Cystic FibrosisVitamin D and Prebiotics for Intestinal Health in Cystic FibrosisCystic Fibrosis;DysbiosisDrug: Vitamin D3;Drug: Placebo vitamin D3;Drug: Inulin;Drug: Placebo InulinEmory UniversityNULLCompleted18 YearsN/AAll40Phase 4United States
2NCT03734744
(ClinicalTrials.gov)
June 17, 20196/11/2018PK/PD of Vitamin D3 in Adults With CFA Pilot Study Evaluating Single, High-dose Pharmacokinetics/Pharmacodynamics of Vitamin D3 in CFVitamin D Deficiency;Cystic FibrosisDietary Supplement: Vitamin D3University of Southern CaliforniaNULLTerminated18 YearsN/AAll6N/AUnited States
3NCT04411901
(ClinicalTrials.gov)
March 1, 201822/5/2020The Role of Vitamin D3 in Pediatric Bronchiectasis SeverityThe Role of Vitamin D3 in Pediatric Bronchiectasis Severity( CF Versus Non CF Bronchioectasis)Cystic Fibrosis and Non CF BronchiectasisDrug: Cholecalciferol (vitaminD3)Heba OmaraNULLCompleted1 Year17 YearsAll40Phase 2/Phase 3Egypt
4NCT02589444
(ClinicalTrials.gov)
December 201520/10/2015Vitamin D and Microbiota in Cystic FibrosisPilot Study Evaluating the Role of Vitamin D Repletion on Gut and Lung Microbiota in Cystic FibrosisVitamin D Deficiency;Cystic FibrosisDietary Supplement: High-Dose Vitamin D3;Other: Stool Sample;Other: Sputum Sample;Other: Sham Comparator;Procedure: Blood drawEmory UniversityNULLCompleted18 YearsN/AAll41N/AUnited States
5NCT01222273
(ClinicalTrials.gov)
September 201014/10/2010Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary AspergillosisOpen-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary AspergillosisCystic Fibrosis;Allergic Bronchopulmonary AspergillosisDietary Supplement: cholecalciferol (Vitamin D3)University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)Completed12 YearsN/AAll7N/AUnited States
6NCT00788138
(ClinicalTrials.gov)
October 20087/11/2008Effects of Vitamin D Supplementation on Lung Function in an Acute Pulmonary Exacerbation of Cystic FibrosisCystic FibrosisDietary Supplement: Vitamin D3;Dietary Supplement: PlaceboEmory UniversityNULLCompleted18 Years70 YearsBoth30N/AUnited States
7NCT00762918
(ClinicalTrials.gov)
March 200826/9/2008Vitamin D3 for the Treatment of Low Vitamin D in Cystic FibrosisVitamin D and Its Non-Classic Roles in Cystic FibrosisCystic Fibrosis;Vitamin D DeficiencyDietary Supplement: cholecalciferolChildren's Hospital of PhiladelphiaNULLWithdrawn10 Years25 YearsBoth0Phase 3United States
8NCT00450073
(ClinicalTrials.gov)
November 200619/3/2007Improving Vitamin D Status In Cystic FibrosisDesktop Tanning Unit to Improve Vitamin D Status in Patients With Cystic Fibrosis and Short Bowel Syndrome: A Pilot StudyCystic FibrosisDrug: ergocalciferol (vitamin D2);Device: Sperti Del Sol Lamp;Drug: Vitamin D3Atlanta VA Medical CenterEmory UniversityCompleted18 Years60 YearsAll30N/AUnited States